Skip to main content
MedPathMedPath Home
Clinical Trials/NCT05451927
NCT05451927
Completed
N/A

A Randomized Double Blind Study to Examine the Effect of Natural Anti-obesity Agent Among Women of Lahore

Hafiza Aisha Sadiqa2 sites in 1 country72 target enrollmentOctober 27, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsOverweight and Obesity

Overview

Phase
N/A
Intervention
Not specified
Conditions
Overweight and Obesity
Sponsor
Hafiza Aisha Sadiqa
Enrollment
72
Locations
2
Primary Endpoint
Body weight
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

This double-blind randomized placebo-controlled trial will test the hypothesis that administration of Phaseolus Vulgaris supplementation to women in Lahore, Pakistan, who are overweight will induce the weight loss (Primary outcome) and changes in body composition (Waist circumference) secondary outcome.

Registry
clinicaltrials.gov
Start Date
October 27, 2022
End Date
December 30, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Hafiza Aisha Sadiqa
Responsible Party
Sponsor Investigator
Principal Investigator

Hafiza Aisha Sadiqa

Student

University of the Punjab

Eligibility Criteria

Inclusion Criteria

  • •BMI ranges from 25-40
  • •Consistently stable body weight for at least 6 months
  • •Good general health
  • •No ongoing drug treatment for weight reduction
  • •Commitment to avoid any changes in lifestyle throughout the test period
  • •Age between 18-45 years
  • •Women resident of Lahore

Exclusion Criteria

  • •Pregnant or breast-feeding females
  • •People with Type 2 diabetes
  • •People with any other chronic diseases
  • •Weight reduction treatment during the 6 months prior to the study

Outcomes

Primary Outcomes

Body weight

Time Frame: 3 months

change in body weight

Study Sites (2)

Loading locations...

Similar Trials

Not Yet Recruiting
N/A
A study to measure markers in the breath of patients with Chronic Obstructive Pulmonary Disease (COPD)
ACTRN12614000617662ung Institute of Western Australia200
Active, Not Recruiting
Phase 1
Effect of testosterone in male patients on regular hemodialysisHypogonadal males undergoing hemodialysis (HD).Therapeutic area: Diseases [C] - Hormonal diseases [C19]
EUCTR2011-005439-20-SEDept of Renal medicine40
Active, Not Recruiting
N/A
A randomised, double-blind study to assess the efficacy and safety of prophylactis use of maribavir versus oral ganciclovir for the prevention of cytomegalovirus disease in recipients of orthotopic liver transplants - NDPatient undergone to orthotopic liver transplantsMedDRA version: 9.1Level: LLTClassification code 10011831Term: Cytomegalovirus infection
EUCTR2007-004729-16-ITVIROPHARMA INCORPORATED348
Active, Not Recruiting
Phase 1
Randomised, double-blind study to demonstrate therapeutic equivalence of formoterol fumarate 12µg capsules delivered by Cyclohaler with Foradil in mild to moderate reversible obstructive airways disease.mild to moderate reversible obstructive airways disease
EUCTR2005-002538-37-GBPharmachemie B.V.30
Active, Not Recruiting
Phase 1
A double blind, placebo controlled study to evaluate the safety and immunogenicity of escalating doses of 108 CFU, 109 CFU and 1010 CFU of M04NM11 in patients who have chronic Hepatitis B infection. - Not AvailableChronic hepatitis B virus infection
EUCTR2005-005293-70-GBEmergent Product Development UK Ltd45